Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 8.

Regan, M M; Neven, P; Giobbie-Hurder, A; Goldhirsch, A; Ejlertsen, B; Mauriac, L; Forbes, J F; Smith, I; Láng, I; Wardley, A; Rabaglio, M; Price, K N; Gelber, R D; Coates, A S; Thürlimann, B (2011). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncology, 12(12):1101-1108.

Regan, M M; Price, K N; Giobbie-Hurder, A; Thürlimann, B; Gelber, R D (2011). Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast Cancer Research, 13(3):209.

Pagani, O; Gelber, S; Simoncini, E; Castiglione-Gertsch, M; Price, K N; Gelber, R D; Holmberg, S B; Crivellari, D; Collins, J; Lindtner, J; Thürlimann, B; Fey, M F; Murray, E; Forbes, J F; Coates, A S; Goldhirsch, A (2009). Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Research and Treatment, 116(3):491-500.

Rabaglio, M; Sun, Z; Price, K N; Castiglione-Gertsch, M; Hawle, H; Thürlimann, B; Mouridsen, H; Campone, M; Forbes, J F; Paridaens, R J; Colleoni, M; Pienkowski, T; Nogaret, J M; Láng, I; Smith, I; Gelber, R D; Goldhirsch, A; Coates, A S (2009). Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Annals of Oncology, 20(9):1489-1498.

Giobbie-Hurder, A; Price, K N; Gelber, R D; et al; Varga, Z; Moch, H; Caduff, R (2009). Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. Clinical Trials, 6(3):272-287.

Mouridsen, H; Giobbie-Hurder, A; Goldhirsch, A; Thürlimann, B; Paridaens, R; Smith, I; Mauriac, L; Forbes, J F; Price, K N; Regan, M M; Gelber, R D; Coates, A S (2009). Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. New England Journal of Medicine, 361(8):766-776.

Pestalozzi, B C; et al; Gelber, R D; Viale, G (2008). Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial. Annals of Oncology, 19(11):1837-1841.

Pestalozzi, B C; Zahrieh, D; Price, K N; Holmberg, S B; Lindtner, J; Collins, J; Crivellari, D; Fey, M F; Murray, E; Pagani, O; Simoncini, E; Castiglione-Gertsch, M; Gelber, R D; Coates, A S; Goldhirsch, A (2006). Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Annals of Oncology, 17(6):935-944.

This list was generated on Tue Mar 26 19:57:29 2019 CET.